IFRX
InflaRxยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
IFRX Profile
Inflarx N.V.
A clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system
Winzerlaer Str. 2, 07745 Jena, Germany
--
InflaRx N.V. was incorporated under the laws of the Netherlands in June 2017 and is a holding company of InflaRx GmbH under the terms of the corporate restructuring. The company is a clinical-stage biopharmaceutical company focused on applying its unique anti-C5a technology to discover and develop a primary, potent and specific inhibitor of a complementary activator called C5a. C5a is a powerful inflammatory mediator involved in the progression of a variety of autoimmune and inflammatory diseases.
